J7637 HCPCS Level II code: Dexamethasone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
J7637 is the HCPCS code for “Dexamethasone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J7637Dexamethasone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
Short description: Dexamethasone comp con
HCPCS · United States
Notes for J7637
As CMS prints them, with any note J7637 takes from the headings above it.
Note
- CMS processing note 0135: MEDICARE BENEFIT POLICY MANUAL, PUB 100.2, CHAPTER 15, SECTION 110.3 (100.02,15,110.3).
Medicare details
The indicators CMS publishes with J7637 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Drugs Administered through DME
- Added
- Jan 1, 2000
Where J7637 sits
- 1J codesDrugs administered other than orally
- 2Active code J7637Dexamethasone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J7637 mean?
J7637 is the HCPCS code for “Dexamethasone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J7637?
CMS lists J7637’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J7637
All J codesJ7631Cromolyn sodium, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 10 milligramsJ7632Cromolyn sodium, inhalation solution, compounded product, administered through dme, unit dose form, per 10 milligramsJ7633Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 0.25 milligramJ7634Budesonide, inhalation solution, compounded product, administered through dme, concentrated form, per 0.25 milligramJ7635Atropine, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7636Atropine, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7638Dexamethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7639Dornase alfa, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligramJ7640Formoterol, inhalation solution, compounded product, administered through dme, unit dose form, 12 microgramsJ7641Flunisolide, inhalation solution, compounded product, administered through dme, unit dose, per milligramJ7642Glycopyrrolate, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7643Glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram